Guru Sonpavde: ctDNA for Evaluating Minimal Residual Disease in Bladder Cancer

Guru Sonpavde, Phase I and GU Oncology Director at Advent Health Cancer Institute, posted on LinkedIn:

“Circulating tumor (ct)-DNA for evaluating MRD (molecular/minimal residual disease) in bladder cancer: In this editorial European Urology, we discuss tumor-informed ctDNA:
1) based on whole-exome sequencing of the tumor,
2) based on whole genome sequencing (WGS) of the tumor and
3) a novel strategy using WGS of tumor and peripheral blood mononuclear cells with subsequent bioinformatics analyses for potentially more accurate ctDNA detection Lars Dyrskjøt Iver Nordentoft – pleased to coauthor from AdventHealth Central Florida cancer Institute– editorial led by Jason Brown– with coauthor Pedro C Barata, MD MSc FACP Lake Health/University Hospital Seidman Cancer Center.”

Visit the article website.
Source: Guru Sonpavde/LinkedIn